Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Central Nervous System (CNS) Cancers

Intended Audience: Oncologists, Surgeons, Pathologists, Community HCPs, Patients/Caregivers

Areas of interest based on referenced literature:

• Management and treatment of CNS cancers
• Role of NTRK gene fusions and impact of TRK-fusion testing in treatment algorithms for local, regional and/or CNS cancers
• Education on biomarker driven testing strategies/appropriate testing modalities
• Multi-disciplinary approach to precision medicine
• Understanding of efficacy and safety profiles of approved TRK inhibitors in local, regional and/or CNS cancers
• Role of Tyrosine Kinase Inhibitors (TKIs) in metastatic CNS cancer treatment algorithms
• Prevention and management of adverse events due to TKIs

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget

Provider Justification:

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic area

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a BHC Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

Management and treatment of CNS cancers

1. 1. NIH – Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: Brain and Other Nervous System Cancer. (link)
2. 2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2019 – September 16, 2019 (link)

Diagnosis, treatment and management of TRK fusion cancer

1. Nagasubramanian R, Wei J, Gordon P, Rastatter JC et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. (link)
2. Hong DS, Bauer TM, Lee JJ et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1;30(2):325-331. (link)
3. Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family protein in cancer. Pharmacol Ther 2017 (173), 58-66. (link)
4. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
5. Cocco, E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (link)
6. Hyman, DM et al. Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer. Annals of Oncology 30 (5), October 2019 (link)
7. Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (link)
8. Ricciuti, B et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019 Apr 30;12:3171-3179 (link)
9. Solomon, JP et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019 Aug 2. (Epub ahead of print) (link)
10. Wong, D et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019 Jun 29. (Epub ahead of print) (link)
11. Drilon, AE et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. Journal of Clinical Oncology 37, 2019 (suppl; abstr 2006) (link)
12. Ziegler DS, Wong M, Mayoh C et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018 Sep;119(6):693-696. (link)
13. Walter, AW et al. Larotrectinib imaging response in low-grade glioma. Pediatr Blood Cancer. 2020 Jan;67(1):e28002(link)
14. Perreault, S. et al. Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumors. ASCO 2021 abstract.(link)
15. Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022 Jun 1;24(6):997-100. (link)
16. Perreault, S. et al. Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors. ASCO 2022 abstract.(link)

    Role of Tyrosine Kinase Inhibitors (TKIs) in CNS cancers

17. Jiang J, et al. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy. 2019 Mar 25:1-17. (link)
18. Lombardi, G et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019 Jan;20(1):110-119. (link)